Physician profile
Marshall Jasper Shuler
NPI 1043335219
$2,601,678.57
in general payments reported to CMS, 2019-2025
38 companies · $550K in 2025
The $550K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361K · 2020: $109K · 2021: $145K · 2022: $425K · 2023: $460K · 2024: $550K · 2025: $550K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.2M · Travel and Lodging: $203K · Consulting Fee: $102K · Food and Beverage: $32K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,520 · Education: $402 · Honoraria: $30.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,220,261.50 |
| Travel and Lodging | $202,760.82 |
| Consulting Fee | $102,401.78 |
| Food and Beverage | $31,756.62 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,520.00 |
| Education | $401.95 |
| Honoraria | $30.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $515,517.25 | 2019-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $464,006.19 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $374,015.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $215,169.70 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $208,898.41 | 2019-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $170,482.09 | 2019-2024 | Tremfya |
| Pfizer INC. | $160,281.78 | 2019-2025 | |
| Ucb, INC. | $127,225.53 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $112,242.68 | 2021-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $94,572.48 | 2019-2025 | Ilumya, Winlevi |
| Leo Pharma INC. | $74,302.66 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Novartis Pharmaceuticals Corporation | $38,046.22 | 2019-2025 | Cosentyx |
| Incyte Corporation | $15,752.40 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $10,937.56 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $7,638.61 | 2024-2025 | Nemluvio |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Shuler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.